XML 29 R19.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value Measurements (Tables)
9 Months Ended
Sep. 30, 2021
Fair Value Disclosures [Abstract]  
Investments Measured at Fair Value on Recurring Basis
Investments, which were measured at fair value on a recurring basis, consisted of the following:
September 30,
2021
December 31,
2020
Fair
Value
Fair Value Measurements UsingFair
Value
Fair Value Measurements Using
(in millions)Level 1Level 2Level 3Level 1Level 2Level 3
Cash and cash equivalents:
Cash and money market funds$311.1 $311.1 $— $— $187.1 $187.1 $— $— 
Restricted cash:
Certificates of deposit3.2 3.2 — — 3.2 3.2 
Debt securities available-for-sale:
Commercial paper208.6 — 208.6 — 82.2 82.2 
Corporate debt securities499.3 — 499.3 — 445.9 445.9 
Securities of government-sponsored entities260.6 — 260.6 — 312.9 312.9 
Equity securities:
Equity securities–biotechnology industry35.3 — — 35.3 38.2 38.2 
$1,318.1 $314.3 $968.5 $35.3 $1,069.5 $190.3 $841.0 $38.2 
Reconciliation of Our Investment in Restricted Equity Securities Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs (Level 3)
The following table presents a reconciliation of equity security investments, which were measured at fair value on a recurring basis using significant unobservable inputs (Level 3):
Three Months Ended
September 30,
Nine Months Ended
September 30,
(in millions)2021202020212020
Balance at beginning of period$38.9 $50.7 $38.2 $55.9 
Purchases (1)
4.6 — 4.6 — 
Unrealized loss included in earnings(8.2)(7.0)(7.5)(12.2)
Balance at end of period$35.3 $43.7 $35.3 $43.7 
_________________________
(1) In September 2021, we purchased 0.3 million shares of Xenon's common stock, valued at $4.6 million on the date of purchase, in connection with the approval of the CTA for NBI-921352.